Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Myelodysplastic-Myeloproliferative Diseases 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Biphenotypic, Acute 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

Cyclophosphamide 53fludarabine phosphate 50Tacrolimus 41Busulfan 41Peripheral Blood Stem Cell Transplantation 37Mycophenolic Acid 36Whole-Body Irradiation 34Antilymphocyte Serum 34Cyclosporine 27Methotrexate 25fludarabine 24Melphalan 20Radiotherapy 19Filgrastim 16Methylprednisolone 14Cord Blood Stem Cell Transplantation 12Cytarabine 11thymoglobulin 10ruxolitinib 10Specimen Handling 10Biopsy 10Cyclosporins 9sargramostim 8Sirolimus 8Etoposide 8Alemtuzumab 8Thiotepa 7Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Myeloproliferative Disorders × decitabine and cedazuridine drug combination × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡